

PHARMANUTRA S.P.A.: ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING AND BOARD OF DIRECTORS' MEETING DOWNSTREAM OF THE SHAREHOLDERS' MEETING

Ordinary shareholders' meeting

- Approval of the project to be admitted to trade on the *Mercato Telematico Azionario*, possibly Star segment;
- Appointment of the Independent Auditor for the financial years 2020 – 2027;
- Appointment of two members of the Board of Directors after co-opting.

Extraordinary shareholder's meeting

- Approval of new articles of association text, effective from the date trading starts on the *Mercato Telematico Azionario*, possibly STAR segment.

Pisa, 13th October 2020 - [PharmaNutra S.p.A.](#) (the "**Company**"), nutraceutical company, leader in the iron nutritional supplements sector, listed on the AIM Italia Market (Ticker: PHN), communicates that the **ordinary and extraordinary Shareholders' Meeting** of the Company held today, in first call, **has approved all proposals on the agenda.**

Ordinary shareholders' meeting

Project to be admitted to trade on the "Mercato Telematico Azionario": the ordinary Shareholders' Meeting has approved the project to be admitted to trade Company shares on the *Mercato Telematico Azionario* organized and managed by Borsa Italiana S.p.A., possibly the STAR segment.

Independent Auditor appointment: the ordinary Shareholders' Meeting, at a motivated proposal made by the Board of Statutory Auditors and after consensual termination of the mandate granted to BDO Italia S.p.A. on 15th April 2019, has appointed said same auditing firm as the independent auditor for the years 2020-2027, subordinate to, and effective from the date trading of Company shares starts on the MTA.

Appointment of two members of the Board of Directors following co-opting: the Ordinary Shareholders' Meeting has confirmed the appointment as Company director, following co-opting by the Board of Directors on 25th September 2020, of Marida Zaffaroni and Giovanna Zanotti, who have declared they hold the independence requirements established by art. 148 of Legislative Decree 58/1998 ("**TUF**"), as

recalled by art. 147 ter of that decree, and by art. 3 of the Voluntary Self-Regulatory Code of Borsa Italiana (jointly, the “**Independence Requirements**”). The Directors appointed shall remain in office until the entire Board of Directors is terminated; hence, until approval of the financial statements for the year closed as at 31st December 2022.

Extraordinary shareholder’s meeting

The extraordinary Shareholders’ Meeting approved the new text of the Articles of Association, coming into effect from the date Company share trading starts on the *Mercato Telematico Azionario* (“**MTA**”), possibly STAR segment.

The Company’s Board of Directors also met today downstream of the aforementioned ordinary and extraordinary Shareholders’ Meeting to: (i) check that its Independent Directors, Alessandro Calzolari, Marida Zaffaroni and Giovanna Zanotti, held Independence Requirements; (ii) appoint Mr Roberto Lacorte as Investor Relator of the Company and, effective subordinate to the start of Company shares being traded on the MTA, the Manager in charge of drawing up the company accounts pursuant to article 154-bis of the TUF, Mr Francesco Sarti.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
investorrelation@pharmanutra.it
Internal Press Office
press@calabughi.com

**Nomad
CFO SIM S.p.A.**

Via dell'Annunciata, 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfsim.com

**Press Office
Spriano Communication & Partners**

Via Santa Radegonda, 16
20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com